

Notice Regarding End of Commissioned Manufacturing of Macromolecular Sodium Hyaluronate

Denka Company Limited (Headquarters: Chuo-ku, Tokyo; President: Toshio Imai; hereinafter, "Denka") has decided to end the commissioned manufacturing of macromolecular sodium hyaluronate at the end of January 2023.

Denka started the commissioned manufacturing of macromolecular sodium hyaluronate in 2000. As the environment surrounding the pharmaceutical market is changing, we determined that it would be difficult to continue stable commissioned manufacturing due to the aging of the manufacturing facilities among other factors, which led to the decision to end the commissioned manufacturing of macromolecular sodium hyaluronate.

Denka positions the healthcare business as one of our priority areas and produces and supplies influenza vaccines, antigen test kits for COVID-19 and the like, G47Δ virus preparation for cancer treatment, and other products in three pillars of prevention, diagnosis and treatment. Going forward, it will focus on those other healthcare businesses.

1. Business overview

Lines of Business	Commissioned manufacturing of macromolecular sodium hyaluronate
Applications	For improving joint function
Production Site	Omi Plant (Itoigawa, Niigata)
Scheduled End of Production:	End of January 2023
Scheduled End of Shipment:	End of March 2023

2. Impact on Business Performance

The impact of this decision on the consolidated forecast for the fiscal year ending March 31, 2023 will be minor.

3. Remarks

Denka will make no personnel reductions as a result of this decision, and it will reassign employees in the commissioned manufacturing business to priority areas for their continued employment. In addition, Denka will continue "uruoi", basic cosmetics business that group company (Denka Cosmetics Limited Company) conducts.

[Inquiries from Media]

Corporate Communications Dept. Tel: +81-3-5290-5511